Director/PDMR Shareholding

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc announced on April 9, 2026, that its Remuneration Committee granted conditional awards under its Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP) to Persons Discharging Managerial Responsibility (PDMRs) on April 7, 2026, at a price of £12.71 per ordinary share. The LTIP Performance Share Plan awards were reduced by 16.2% due to recent share price volatility, with the Remuneration Committee retaining discretion to adjust outcomes further. Specific awards were granted to Said Darwazah (158,336 LTIP, 28,149 DBP), Mazen Darwazah (126,364 LTIP, 36,135 DBP), Khalid Nabilsi (100,792 LTIP), Hussein Arkhagha (59,221 LTIP), Bassam Kanaan (88,860 LTIP), Susan Ringdal (49,502 LTIP), Julie Hill (40,043 LTIP), Hafrun Fridriksdottir (87,317 LTIP), and Sam Park (61,940 LTIP, 23,000 LTIP Conditional).

Disclaimer*

Hikma Pharmaceuticals Plc
09 April 2026
 

 

Hikma Pharmaceuticals PLC - Discretionary Share Awards

 

LONDON, 9 April 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") and the 2023 Deferred Bonus Plan (the "DBP") to Persons Discharging Managerial Responsibility ("PDMRs") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 7 April 2026 based on a price of £12.71 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 7 April 2026, in accordance with the LTIP rules) (the "LTIP Awards"). All LTIP Awards are subject to the continued employment of the PDMR and malus and clawback provisions.

LTIP Performance Share Plan ("PSP") Awards are subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP (PSP) Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP (PSP) Awards are then subject to an additional two-year holding period. LTIP (Conditional) Awards will normally vest on the second anniversary of the date of grant.

Taking into account the recent share price volatility and the absolute and relative fall in the Company's share price since the prior year grant of LTIP Awards, the Remuneration Committee has scaled back the level of the LTIP (PSP) Awards for the PDMRs. The share awards have been reduced by 16.2%, equating to half the share price decline since the prior year LTIP grant. The Remuneration Committee also retains discretion to further adjust award outcomes at vesting to take into account windfall gains if necessary.

Awards under the DBP were made on 7 April 2026 based on a price of £12.71 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 7 April 2026, in accordance with the DBP rules) (the "DBP Awards"). The vesting of the DBP Awards is subject to the continued employment of the PDMRs, and malus and clawback provisions. The DBP Awards will normally vest on the third anniversary of the date of grant.

 

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 158,336

Nil

DBP Award: 28,149

d)

Aggregated information

Price(s): Nil

Volume(s): 186,485

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman and Deputy CEO, MENA

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and DBP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 126,364

Nil

DBP Award: 36,135

d)

Aggregated information

Price(s): Nil

Volume(s): 162,499

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

Deputy CEO, North America and Europe

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 100,792

d)

Aggregated information

Price(s): Nil

Volume(s): 100,792

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Hussein Arkhagha

 1

 Details of the person discharging managerial responsibilities / person closely associated

 a)

Name

Hussein Arkhagha

 2

 Reason for the notification

 a)

Position/status

PDMR

 b)

Initial notification   /Amendment

Initial notification

 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)

 Name

Hikma Pharmaceuticals PLC

 b)

 LEI

549300BNS685UXH4JI75

 4

   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 59,221

d)

Aggregated information

Price(s): Nil

Volume(s): 59,221

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 88,860

d)

Aggregated information

Price(s): Nil

Volume(s): 88,860

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 49,502

d)

Aggregated information

Price(s): Nil

Volume(s): 49,502

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Julie Hill

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Julie Hill

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 40,043

d)

Aggregated information

Price(s): Nil

Volume(s): 40,043

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Hafrun Fridriksdottir

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hafrun Fridriksdottir

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 87,317

d)

Aggregated information

Price(s): nil

Volume(s): 87,317   

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

Sam Park

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sam Park

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP (PSP) Award: 61,940  

Nil

LTIP (Conditional) Award: 23,000

d)

Aggregated information

Price(s): nil

Volume(s): 84,940 

e)

Date of the transaction

7 April 2026

f)

Place of the transaction

Outside a trading venue

 

 

Helen Middlemist

Group Company Secretary
+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings